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Abstract: Background Prognosis of patients affected by metastatic esophageal-gastric junction (EGJ) or
gastric cancer (GC) remains dismal. Trastuzumab, an anti-HER2 monoclonal antibody, is the only tar-
geted agent approved for the first-line treatment of patients with HER2-overexpressing advanced EGJ or
GC in combination with chemotherapy. However, patients invariably become resistant during this treat-
ment. We recently identified the overexpression of fibroblast growth factor (FGF) receptor 3 (FGFR3)
as a molecular mechanism responsible for trastuzumab resistance in GC models, providing the rationale
for the inhibition of this receptor as a potential second-line strategy in this disease. Pemigatinib is a
selective, potent, oral inhibitor of FGFR1, 2, and 3. Methods The FiGhTeR trial is a phase II, single-
arm, open-label study to assess safety and activity of the FGFR inhibitor pemigatinib as second-line
treatment strategy in metastatic EGJ/GC patients progressing under trastuzumab-containing therapies.
The primary endpoint is the 12-week progression-free survival rate. Plasma and tumor tissue samples
will be collected for translational research analyses at baseline, during treatment, and at progression
on pemigatinib. Discussion Co-alterations in genes coding for different tyrosine-kinase receptors are
emerging as relevant mechanisms of acquired resistance to anti-HER2 therapeutic strategies in GC. In
particular, our group has recently identified that in GC models the overexpression of FGFR3 sustains
the acquired resistance to trastuzumab. This trial aims to assess the safety, tolerability and activity
of the FGFR inhibitor pemigatinib as a second-line treatment in metastatic EGJ/GC patients refrac-
tory to first-line trastuzumab-containing therapies. Furthermore, this study offers the opportunity to
prospectively study mechanisms and pathways involved in trastuzumab resistance. Protocol number
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Abstract
Background: Prognosis of patients affected by metastatic esophageal–gastric junction (EGJ) 
or gastric cancer (GC) remains dismal. Trastuzumab, an anti-HER2 monoclonal antibody, 
is the only targeted agent approved for the first-line treatment of patients with HER2-
overexpressing advanced EGJ or GC in combination with chemotherapy. However, patients 
invariably become resistant during this treatment. We recently identified the overexpression of 
fibroblast growth factor (FGF) receptor 3 (FGFR3) as a molecular mechanism responsible for 
trastuzumab resistance in GC models, providing the rationale for the inhibition of this receptor 
as a potential second-line strategy in this disease. Pemigatinib is a selective, potent, oral 
inhibitor of FGFR1, 2, and 3.
Methods: The FiGhTeR trial is a phase II, single-arm, open-label study to assess safety and 
activity of the FGFR inhibitor pemigatinib as second-line treatment strategy in metastatic EGJ/
GC patients progressing under trastuzumab-containing therapies. The primary endpoint is the 
12-week progression-free survival rate. Plasma and tumor tissue samples will be collected 
for translational research analyses at baseline, during treatment, and at progression on 
pemigatinib.
Discussion: Co-alterations in genes coding for different tyrosine-kinase receptors are 
emerging as relevant mechanisms of acquired resistance to anti-HER2 therapeutic strategies 
in GC. In particular, our group has recently identified that in GC models the overexpression 
of FGFR3 sustains the acquired resistance to trastuzumab. This trial aims to assess the 
safety, tolerability and activity of the FGFR inhibitor pemigatinib as a second-line treatment 
in metastatic EGJ/GC patients refractory to first-line trastuzumab-containing therapies. 
Furthermore, this study offers the opportunity to prospectively study mechanisms and 
pathways involved in trastuzumab resistance.
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Background
Gastric cancer (GC) constitutes a major global 
health problem as it remains the fifth most-fre-
quently diagnosed cancer and the third leading 
cause of cancer-related deaths worldwide.1 
Systemic chemotherapeutic and targeted agents 
provide a significant improvement in survival for 
patients with metastatic GC. However, this dis-
ease inevitably progresses under these treatments, 
so that the prognosis of metastatic GC patients 
remains unfavorable with a 5-year overall survival 
(OS) rate around 5–20%.2
Human epidermal growth factor receptor 2 
(HER2), also known as p185 or ErbB-2, is a 
transmembrane tyrosine kinase receptor of 185 
kDa and is encoded by the proto-oncogene HER2/
neu mapped on chromosome 17q21; it belongs to 
the epidermal growth factor receptor family.3,4 In 
GC, HER2 overexpression is present in a percent-
age that varies between 7% and 34% of the cases.5
Trastuzumab, a recombinant humanized mono-
clonal antibody directed against HER2, is the only 
targeted agent approved for the first-line treat-
ment of patients with HER2-overexpressing meta-
static GC in combination with chemotherapy. 
The ToGA trial demonstrated that the addition of 
trastuzumab to a doublet chemotherapeutic regi-
men with cisplatin and fluoropyrimidine improves 
OS, progression-free survival (PFS), and response 
rate (RR) in HER2-positive metastatic gastric or 
gastroesophageal junction adenocarcinoma.6
If primary resistance to trastuzumab is quite rare in 
patients with HER2 overexpression, almost all 
patients become resistant after a certain period of 
therapy. It has been shown that the selection of 
HER2 not amplified clones is a common mecha-
nism of trastuzumab resistance.7,8 In particular, 
patients with uncertain basal immunohistochemis-
try positivity (IHC 2+) seem to frequently lose 
amplified HER2 clones. Furthermore, in the same 
patient the loss of amplified HER2 clones may be 
due to tumor progression or tumor heterogeneity 
between metastatic and primary tumor.9 Additional 
mutations in receptor tyrosine kinases, RAS and 
PI3K pathways are emerging as relevant mecha-
nisms of both intrinsic and acquired resistance to 
anti-HER2 therapies. Patients with these co-alter-
ations have a lower benefit from receiving trastu-
zumab and are characterized by a shorter PFS.10
Fibroblast growth factor (FGF) receptor 3 
(FGFR3) is a member of a family of four tyrosine 
kinase receptors that are implicated in cellular 
growth and survival and tumor angiogenesis.11 
FGF family includes heparin-binding polypeptide 
ligands, including FGF9, that has a unique affin-
ity for FGFR3.12 We recently demonstrated in 
GC that the overexpression of FGFR3 and FGF9 
activating the PI3K/AKT/mTOR signaling path-
way sustains acquired resistance to trastuzumab. 
In our study, GC models selected for resistance to 
trastuzumab were shown to be associated with 
overexpression of FGFR3, FGF9, and phospho-
rylated AKT, in addition to losing HER2 expres-
sion. In vivo, trastuzumab-resistant murine models 
treated with dovitinib, a selective inhibitor of 
FGFR3, showed a higher reduction in tumor bur-
den and longer OS compared with the control 
group. The relevance of FGFR3 overexpression 
has been demonstrated in a clinical setting, com-
paring biopsies at baseline and after progression to 
trastuzumab in three patients. In all these patients, 
biopsies collected at trastuzumab progression 
exhibited significantly higher FGFR3 expression 
than their matched pretreatment samples.13
This preclinical evidence led to the design of 
the FiGhTeR trial, which aims to assess the 
safety, tolerability and activity of pemigatinib 
(INCB54828), an inhibitor of FGFR1, 2, and 3, 
in metastatic esophageal–gastric junction (EGJ)/
GC patients refractory to first-line trastuzumab-
containing therapies.
Many studies have provided evidence for an increas-
ing role of FGFR signaling as a key mediator of 
resistance to anti-HER2 therapies. Pemigatinib 
(INCB054828) is a potent and selective inhibitor of 
the FGFR family members. The FiGhTeR trial 
aims to assess the safety and activity of the FGFR 
inhibitor pemigatinib in HER2 trastuzumab-resist-
ant GC patients. Translational research analyses on 
plasma and tissue specimens collected in this study 
will be used to identify novel molecular mechanisms 
responsible for trastuzumab resistance and predic-
tive biomarkers of pemigatinib in GC patients.
Methods/design
Study setting
The FiGhTeR trial is a phase II, single-arm, open-
label study to assess safety, tolerability, and activity 
of pemigatinib as second-line treatment strategy in 
metastatic EGJ/GC patients refractory to first-line 
trastuzumab-containing therapies. Patients will be 
screened for eligibility by research staff to ensure 
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that all inclusion and exclusion criteria are met. 
Main eligibility criteria include disease progression 
within 3 months of the last dose of first-line trastu-
zumab-containing therapy, fresh biopsy available, 
and adequate bone marrow, liver, and renal func-
tion (Table 1). Exclusion criteria include corneal 
disorders, serious cardiovascular disease, elevated 
serum phosphate and calcium levels (Table 2).
This is a single-institution trial conducted at the 
early phase clinical trial unit “Centro Ricerche 
Cliniche di Verona” at the University Hospital of 
Verona, Italy.
All reporting will adhere to the Consolidated 
Standards of Reporting Trials (CONSORT) 
guideline.14 The study protocol follows the 
Standard Protocol Items: Recommendations for 
Interventional Trials (SPIRIT) guidance for pro-
tocol reporting (see Supplemental Figure S1).15
Study treatment
All patients receive self-administered, oral pemi-
gatinib at a dose of 13.5 mg once daily (21-day 
cycle; 2 weeks on, 1 week off), until radiologic dis-
ease progression, unacceptable toxicity, withdrawal 
of consent, or patient/physician choice. This 
dose regimen was supported by pharmacokinetic/
pharmacodynamic results from a phase I/II study of 
pemigatinib for metastatic malignancies.16 In cases 
where study drug should be restarted at a next lower 
dose, the new doses can be 9 mg and then 6 mg 
(Table 3). Concomitant potent CYP3A4 inhibitors 
and inducers are prohibited. Other anticancer med-
ications and study drugs are prohibited. Compliance 
with the study treatments is emphasized to the par-
ticipant by the site personnel. Participants are 
instructed to bring the study drug with them to the 
study visits so that site personnel can conduct tablet 
counts to assess study drug accountability.
Follow-up and study assessment
The patients at the screening undergo a physical 
exam, a 12-lead ECG, blood count, serum chem-
istry and a CT or MRI radiological tumor assess-
ment. Before every cycle of treatment, the patients 
undergo a physical exam, blood count, serum 
chemistry, and adverse event evaluation. Disease 
assessment is performed every 6 weeks for the first 
4 cycles, and then every 9 weeks by using CT or 
MRI scan. All study assessments are performed as 
indicated in the schedule of assessments (Table 4).
Endpoints
The primary endpoint is the 12-week PFS rate, 
which is the probability of being without pro-
gression (loco-regional or distant) or death due 
to any cause at 12 weeks from trial enrollment. 
The secondary endpoints are OS, disease  control 
Table 1. Eligibility criteria.
 1. Histologically confirmed advanced or metastatic adenocarcinoma of the stomach and the 
gastroesophageal junction.
 2.  Disease progression within 3 months of the last dose of first-line trastuzumab-containing therapy.
 3.  Patients must have performed a fresh biopsy (at least 8–10 slides with >20% tumor content) at the 
baseline of study enrollment.
 4.  At least one measurable and evaluable disease site based on response evaluation criteria in solid 
tumors (RECIST v1.1).
 5.  Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0–1.
 6.  Age ⩾18, no age upper limit unless patient would be unable to tolerate chemotherapy.
 7.  An expected survival of more than 3 months.
 8.  Duration from the last therapy is more than 4 weeks for other cytotoxic agents, surgery, or 
radiotherapy.
 9.  Major organ function has to meet the following criteria hemoglobin (Hb)>8 g/dl, platelet count 
>75 × 109/l, neutrophil count >1.5 × 109/L
10.  Absence of pregnancy or breastfeeding.
11. Pregnancy test (serum or urine) must be performed for woman of childbearing age within 7 days 
before enrolment and the test result must be negative. They shall take appropriate methods for 
contraception during the study until the 8th week after the last administration of study drug. For men, 
shall agree to take appropriate methods of contraception during the study until the 8th week after the 
last administration of study drug.
12. Patients must be accessible to follow-up and management in the treatment center.
13. Patient must voluntarily join the study and sign the informed consent form for the study
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Table 2. Exclusion criteria.
 1.  Current evidence of corneal disorder/keratopathy, including but not limited to bullous/band 
keratopathy, corneal abrasion, inflammation/ulceration, keratoconjunctivitis, etc., confirmed by 
ophthalmologic examination.
 2. Any active malignancies except cured basal cell carcinoma of skin and carcinoma in situ of uterine 
cervix.
 3. Poorly controlled arterial hypertension (systolic blood pressure >140 mmHg and diastolic blood 
pressure >90 mmHg) despite standard medical management.
 4. Serious cardiovascular disease: II level myocardial ischemia or myocardial infarction, arrhythmia 
(including QT interval prolongation, for man >450 ms, for woman >470 ms); III–IV level cardiac 
function insufficiency, or echocardiography showed that left ventricular ejection fraction (LVEF) <50%.
 5. Positive urinary protein (urine protein detection of 2 or more, or 24-hour urine protein > 1.0 g).
 6. Total bilirubin ⩾1.5 × upper limit of normal (ULN; ⩾2.5 × ULN if Gilbert syndrome or metastatic 
disease involving liver).
 7. AST and ALT >2.5 × ULN (AST and ALT >5 × ULN in the presence of liver metastases).
 8. Creatinine clearance ⩽30 ml/min based on Cockcroft–Gault.
 9. Factors that could have an effect on oral medication (such as inability to swallow, chronic diarrhea, 
and intestinal obstruction).
10. Serum phosphate > institutional ULN.
11. Serum calcium outside of the institutional normal range or serum albumin-corrected calcium outside 
of the institutional normal range when serum albumin is outside of the institutional normal range.
12. History of calcium/phosphate homeostasis disorder.
13. History and/or current evidence of ectopic mineralization/calcification, including but not limited to 
soft tissue, kidneys, intestine, myocardia, or lung, excepting calcified lymph nodes and asymptomatic 
arterial or cartilage/tendon calcification.
14. Current evidence of significant corneal disorder/keratopathy or retinal disorder, confirmed by 
ophthalmologic examination.
15. Factors of high gastrointestinal bleeding risk, including the following conditions: local active ulcer 
lesions with positive fecal occult blood test (++); history of black stool, or vomiting blood in the past 
2 months; unresected primary lesion in stomach with positive fecal occult blood test (+), ulcerated 
gastric carcinoma with massive alimentary tract bleeding risk judged by Pis based on gastric 
endoscopy result.
16. Abnormal Coagulation (INR > 1.5 APTT > 1.5 UNL), with tendency of bleed.
17. Known hypersensitivity or severe reaction to INCB054828 or excipients of INCB054828 study drug
18. Any psychological, familial, sociological or geographical condition potentially hampering compliance 
with the study protocol and follow-up schedule; those conditions should be discussed with the patient 
before registration in the trial.
Table 3. Guidelines for interruption and restarting of study drug.
Adverse event Action taken
Chemistry  
AST and/or ALT is >5.0 × ULN Step 1: interrupt study drug up to 14 days until the toxicity has resolved to 
⩽Grade 1 except by approval of the medical monitor
Step 2: restart study drug at same dose. If assessed related to study drug, 
restart study drug at next lower dose; monitor as clinically indicated
Other toxicities  
Any Grade 1 or Grade 2 
toxicity
Continue study drug treatment and treat the toxicity; monitor as clinically 
indicated
Any Grade 3 toxicity if 
clinically significant and not 
manageable by supportive 
care
Step 1: interrupt study drug up to 14 days until the toxicity has resolved to 
⩽Grade 1
Step 2: restart study drug at same dose. If assessed related to study drug, 
restart study drug at next lower dose; monitor as clinically indicated
Any recurrent Grade 3 toxicity 
after two dose reductions
Discontinue study drug administration and follow-up per protocol
Any other Grade 4 toxicity Discontinue study drug administration and follow-up per protocol
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rate (DCR), and safety profile (incidence of 
⩾grade 3 adverse events using Common 
Terminology Criteria for Adverse Events - CTCAE 
- version 4.0).
Other exploratory objectives include collecting 
and banking serial blood and tumor tissue speci-
mens from participants at baseline and at the time 
of pemigatinib progression for correlative bio-
marker studies.
Statistical design and sample size
Simon’s two-stage design is used. The null hypothe-
sis that the 12-weeks PFS rate is 20% is tested against 
a one-sided alternative. The optimal two-stage design 
to test the null hypothesis that p ⩽ 0.200 versus the 
alternative that p ⩾ 0.50 has an expected sample size 
of 10.03 and a probability of early termination of 
0.797. If the drug is actually ineffective, there is a 
0.039 probability of concluding that it is (the target 
for this value was 0.05). If the drug is actually effec-
tive, there is a 0.2 probability of concluding that it is 
not (the target for this value was 0.2). After testing 
the drug on 8 patients in the first stage, the trial will 
be terminated if there are 2 or fewer patients progres-
sion free at 12 weeks. If the trial goes on to the second 
stage, a total of 18 patients will be studied. If the total 
number of progression-free patients at 12 weeks is 
less than or equal to six, the drug is rejected.
Table 4. Schedule of assessments.
Screening Treatment EOT Follow-up
 Cycle 1 Cycle 2 Safety Disease status Survival
Procedures Days −28
to −1








Every 9 weeks Every 
12 weeks
Pemigatinib D1–D14 D1–D14  
Informed consent X  
Demographics X  
Medical history X  
Concurrent meds X X X X X X  
Physical exam X X X X X X X  
Vital signs X X X X X X X  
Height X  
Weight X X X X X X X  
ECOG
Performance status
X X X X X X X  
Blood count X X X X X X X  
Serum chemistry X X X X X X X  
Coagulation panel X  
Urinalysis X  
12- lead ECG X X X X X  
Adverse event 
evaluation
X X X X X X  
Radiological tumor 
assessment
X X (every 2 cycles 
through Cycle 4,
every 3 cycles 
thereafter)
X (only for 
participant who 
discontinue for 
a reason other 
than PD)
 
Therapeutic Advances in Medical Oncology 12
6 journals.sagepub.com/home/tam
Safety assessment
All adverse events observed must be reported in 
the patients’ medical records and in electronic 
case report forms (eCRFs). All serious adverse 
events (SAEs) occurring during the study treat-
ment period must be reported within 24 h.
The inhibition of FGFR is responsible for specific 
on-target adverse events of pemigatinib. Prelimi-
nary results from the phase I/II FIGHT-101 
[INCB 54828-101, ClinicalTrials.gov identifier: 
NCT02393248] study have been reported. In 
parts 1 and 2 combined, in which pemigatinib 
was used alone, the most frequent adverse events 
were hyperphosphatemia (61%; all at doses 
⩾6 mg), fatigue (39%), dry mouth (31%), alope-
cia (28%), constipation (23%), and stomatitis 
(21%).16 Most frequent CTCAE grade ⩾3 
adverse events were fatigue (10%), pneumonia 
(8%), and hyponatremia (7%).
Hyperphosphatemia is an expected on-target 
pharmacologic effect of FGFR inhibition. It 
should be managed with diet modifications, 
phosphate-binding therapy, dose reductions, or 
interruptions (Table 5). Liver chemistries, includ-
ing serum levels of ALT, AST, and bilirubin, are 
assessed on a regular basis. A baseline compre-
hensive ophthalmology examination is obtained 
at baseline and on a regular basis while receiving 
pemigatinib. The plasmatic levels of phosphate, 
calcium, vitamin D3, and parathyroid hormone 
are monitored regularly.
Data management, control of data consistency, 
quality control, monitoring, and audits
The investigator is responsible for ensuring data 
quality. All information required the protocol are 
entered in the eCRF. Periodic monitoring visits at 
the center are planned. Monitoring procedures 
will be adapted to the study-specific risks for 
patients. Standard operating procedures (SOPs) 
will be interpreted to ensure patient safety and the 
integrity of the clinical data. The investigator or a 
designated representative is obliged to provide 
clarification or respond to queries. If no further 
corrections are to be made in the database, it will 
be locked and used for statistical analysis.
Ethics approval and consent to participate
This study is conducted in accordance with the 
1964 Declaration of Helsinki and Ethical Guidelines 
for Medical and Health Research Involving Human 
Subjects. The study received approval on May 7, 
2019 by Ethics Committee of Verona and Rovigo 
(protocol number CRC2017_02, v.1.1). All patients 
will provide written informed consent before enroll-
ment. The investigator will inform patients that par-
ticipation in the trial is voluntary and that they can 
withdraw at any time. They will be informed that 
Table 5. Recommended approach for hyperphosphatemia management.




>5.5 mg/dl and ⩽7 mg/dl Initiate a low-phosphate diet No action Not applicable
>7 mg/dl and ⩽10 mg/dl Initiate/continue a low-phosphate 
diet and initiate phosphate binding. 
Monitor serum phosphate at least 
twice a week and adjust the dose 
of binders as needed; continue to 
monitor serum phosphate at least 
twice a week until return to normal 
range
If serum phosphate level continues 
to be >7 mg/dl and ⩽10 mg/dl with 
concomitant phosphate-binding 
therapy for 2 weeks, or if there is 
recurrence of serum phosphate 
level in this range, interrupt 
pemigatinib for up to 2 weeks
Restart at the same 
dose when serum 
phosphate is <7 mg/
dl. If serum phosphate 
level recurs at >7 mg/
dl, restart study drug 
with dose reduction
>10 mg/dl Continue to maintain a low-
phosphate diet, adjust phosphate-
binding therapy, and start/continue 
phosphaturic agent. Continue to 
monitor serum phosphate at least 
twice a week until return to normal 
range
If serum phosphate level is 
>10 mg/dl for 1 week following 
phosphate-binding therapy and 
low-phosphate diet, interrupt 
study drug. If there is recurrence 
of serum phosphate level 
in this range following two 
dose reductions, permanently 
discontinue pemigatinib
Restart study drug 
at reduced dose 
with phosphate 
binders when serum 
phosphate is <7 mg/dl.
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the investigator will maintain their records over the 
long-term follow-up period and that their records 
may be viewed by management officers, within the 
limits of regulations. The privacy of patients will be 
protected. The written consent will include the per-
mission of collecting and use data and biological 
data. This study is carried out in accordance with 
International Conference on Harmonization Good 
Clinical Practice (ICH-GCP). Every amendment in 
the research protocol will be first submitted to 
Research Ethics Committee approval. To avoid 
breaking data confidentiality only Principal 
Investigator will have access to the final study data-
base, which will be typed into online (REDCap) 
with restrictive access passwords.
Translational research analyses
An extensive program of translational research is 
planned. In order to identify novel potential 
mechanisms of resistance to trastuzumab and 
pemigatinib, tissue and blood samples from 
enrolled patients are collected at baseline after 
progression under treatment with trastuzumab, 
along the treatment, and at disease progression 
under treatment with pemigatinib (Figure 1).
To prospectively evaluate new potential biomark-
ers and study the dynamic nature of therapeutic 
resistance in metastatic GC, immunohistochem-
istry (IHC) and next-generation sequencing 
(NGS) on tumor samples are performed. In order 
to correlate pemigatinib response to genomic and 
epigenomic profiling of patients with trastu-
zumab-resistant GC, biopsies are analyzed for 
mutational and epigenetic status through NGS 
analysis and chromatin immunoprecipitation 
(ChIP) sequencing, respectively. To identify 
potential biomarkers of response to pemigatinib, 
genomic findings are correlated with treatment 
response and patient outcomes.
To overcome a possible limitation depending 
on tumor heterogeneity, NGS analysis of free 
Figure 1. Schema of study treatment and timeline of blood and tumor samples collection for translational 
analyses.
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circulating tumor DNA (ctDNA) is performed on 
liquid biopsies of plasma from enrolled patients.
Discussion
GC remains one of the most lethal solid tumors 
worldwide.17 Trastuzumab contributed to 
improve prognosis of patients with HER2-positive 
GC; however, resistance to this monoclonal anti-
body remains one of the major challenges in this 
setting. To date, no specific targeted therapies are 
available after failing trastuzumab-containing reg-
imens.18–20 Our group recently identified the 
FGFR3/AKT axis as an escape pathway responsi-
ble for trastuzumab resistance in GC, laying the 
basis for testing FGFR3 inhibition as a potential 
strategy to modulate this resistance.13
The mammalian FGFR family includes four 
highly conserved receptors (FGFR1, FGFR2, 
FGFR3, and FGFR4) that have an extracellular 
ligand binding domain, a single transmembrane 
domain and an intracellular tyrosine kinase 
domain. Eighteen FGF ligands bind to FGFRs 
leading to receptor dimerization, activation of the 
kinase domain and transphosphorylation of the 
receptors. FGFRs are involved in the regulation of 
cell survival, proliferation, differentiation and 
motility during embryogenesis, adult-tissue home-
ostasis, and carcinogenesis. There is a strong 
genetic and functional evidence that dysregulation 
of FGFR can lead to the establishment and pro-
gression of cancer. Genetic alterations in FGFR1, 
FGFR2, and FGFR3 have been described in 
many tumor types.11 Further studies have pro-
vided evidence for an increasing role of FGFR 
signaling as a key mediator of resistance to several 
drugs, including anti-HER2 therapies.21–23
Recently, signals of activity from targeting FGFR 
pathway in GC has been reported. The monoclo-
nal antibody bemarituzumab showed activity in 
high FGFR2b-overexpressing advanced gastroe-
sophageal junction adenocarcinoma in a phase I 
study.24
Pemigatinib (INCB054828) is a potent and selec-
tive inhibitor of the FGFR family members. In 
vitro, pemigatinib inhibits the kinase activity of 
FGFR1, FGFR2, and FGFR3 with IC50 values 
that ranged from 0.39 to 1.2 nM, while it has a 
minor inhibitory potency against FGFR4. Safety 
and activity of pemigatinib have been assessed in a 
number of complete and ongoing clinical trials. 
FIGHT-101 was a three-part, phase I/II study that 
showed preliminary safety and efficacy data of 
pemigatinib in patients with metastatic solid tumors 
(parts 1 and 3) or tumors with FGF/FGFR altera-
tion (part 2), of which the most common were 
cholangiocarcinoma, breast, esophageal, ovarian, 
and head and neck cancer. In part 1, no patients 
had a complete response (CR) or partial response 
(PR), while in part 2 three patients showed PR. 
Most frequent adverse events were hyperphos-
phatemia, anemia, diarrhea, fatigue, dehydration, 
constipation, nausea, and vomiting.16
Two phase II studies tested pemigatinib in solid 
tumors in which FGFR alterations seem to have 
an important pathogenetic role. FIGHT-201 
[INCB 54828-201, ClinicalTrials.gov identifier: 
NCT02872714] is an ongoing phase II study 
evaluating the efficacy and safety of pemigatinib 
in participants with metastatic or surgically unre-
sectable urothelial carcinoma failing at least one 
therapy or platinum ineligible and harboring 
FGF/FGFR alterations. Interim results showed 
that the drug was well-tolerated and preliminary 
data of efficacy have been presented. In cohort A 
(patients with FGFR3 mutations/fusions) overall 
response rate (ORR) was 25%.25
FIGHT-202 [INCB 54828-202, ClinicalTrials.
gov identifier: NCT029243769] was a phase II 
study that aimed to test efficacy and safety of 
pemigatinib in participants with advanced or 
metastatic or surgically unresectable cholangio-
carcinoma who failed at least one previous ther-
apy. In cohort A, which included patients with 
FGFR2 fusions or rearrangements, ORR was 
35.5% (95% CI 26.5−45.4%), with 3 complete 
responses and 32.7% of partial responses, and 
DCR was 82% (95% CI 74%−89%); median 
PFS and OS reported were respectively 6.9 (95% 
CI 6.2–9.6) and 21.1 (14.8 not reached; OS not 
mature at cutoff) months.26 On the basis of these 
results, FIGHT-302 trial [ClinicalTrials.gov 
identifier: NCT03656536] has been started. It is 
a phase III study comparing pemigatinib versus 
gemcitabine plus cisplatin chemotherapy in first-
line treatment of patients with unresectable or 
metastatic cholangiocarcinoma with FGFR2 
rearrangement.
FiGhTeR trial aims to assess safety and activity of 
the FGFR inhibitor pemigatinib in HER2 trastu-
zumab-resistant GC patients. Achieving the 
primary endpoint of 12-week PFS would lay 
the basis for a practice changing GC treatment 
strategy.
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One major open area for discussion is the lack of 
patients’ selection based on FGFR3 genetic alter-
ations in tumor or liquid biopsy at baseline. While 
several other studies with pemigatinib have 
among the inclusion criteria the detection of 
FGFR alterations in the tumor tissue, we decided 
not to include this criterion in our study. In our 
preclinical study, indeed, FGFR3 overexpression 
in GC models selected for resistance to trastu-
zumab was not due to a gene amplification or 
rearrangement. Thus, selecting patients using a 
genomic profiling assay could exclude patients 
that may benefit from this therapeutic strategy. 
Moreover, recent studies demonstrated that 
FGFR3 genetic alterations such as mutations or 
copy-number variation could be identified only in 
6–7% of GC patients at baseline. Circulating 
tumor DNA profiling in pre- versus post-progres-
sion plasma samples from patients treated with 
trastuzumab demonstrated no difference in 
FGFR3 alterations rates.27 In this regard, we 
hypothesize that the overexpression of FGFR3 
and its ligand FGF9 could be a dynamic compen-
satory mechanism independent from preexistent 
of acquired genetic alterations. Thus, patients are 
enrolled in the FiGhTeR trial without any genetic 
selection. Patients will be adequately informed at 
the screening phase about the lack of evidence of 
a certain FGFR3 expression in all trastuzumab 
resistant patients. Translational research analyses 
on plasma and tissue specimens collected in this 
study will be used to identify novel molecular 
mechanisms responsible for trastuzumab resist-
ance and predictive biomarkers of response to 
pemigatinib in GC patients.28 Overall, we believe 
that this study could offer an additional therapeu-
tic option to trastuzumab resistant GC patients, 
for whom no many other effective therapies are 
actually available.
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